National practice patterns and direct medical costs for prostate cancer in Korea across a 10 year period: a nationwide population-based study using a national health insurance database
Authors:
- Ho Won KangHKHo Won Kang
- Seok-Joong YunSYSeok-Joong Yun
- Jae Il ChungJCJae Il Chung
- Hoon ChoiHCHoon Choi
- Jae Heon KimJKJae Heon Kim
- Ho Song YuHYHo Song Yu
- Yun-Sok HaYHYun-Sok Ha
- In-Chang ChoICIn-Chang Cho
- Hyung Joon KimHKHyung Joon Kim
- Hyun Chul ChungHCHyun Chul Chung
- Jun Sung KohJKJun Sung Koh
- Wun-Jae KimWKWun-Jae Kim
Open Access
- 24 June 2019
- journal article
- research article
- Published by Springer Nature in BMC Health Services Research
- Vol. 19 (1) , 1-11
Abstract
Background: A complete enumeration study was conducted to evaluate trends in national practice patterns and direct medical costs for prostate cancer (PCa) in Korea over a 10-year retrospective period using data from the Korean National Health Insurance Service. Methods: Reimbursement records for 874,924 patients diagnosed between 2002 and 2014 with primary PCa according to the International Classification of Disease (ICD) 10th revision code C61 were accessed. To assess direct medical costs for patients newly diagnosed after 2005, data from 68,596 patients managed between January 2005 and 31 December 2014 were evaluated. Results: From 2005 to 2014, the total number of PCa patients showed a 2.6-fold increase. Surgery and androgen deprivation therapy were the most common first-line treatment, alone or within the context of combined therapy. Surgery as a monotherapy was performed in 23.5% of patients in 2005, and in 39.4% of patients in 2014. From 2008, the rate of robot-assisted RP rose sharply, showing a similar rate to open RP in 2014. Average total treatment costs in the 12 months post-diagnosis were around 10 million Korean won. Average annual treatment costs thereafter were around 5 million Korean won. Out-of-pocket expenditure was highest in the first year post-diagnosis, and ranged from 12 to 17% thereafter. Conclusions: Between 2005 and 2014, a substantial change was observed in the national practice pattern for PCa in Korea. The present data provide a reliable overview of treatment patterns and medical costs for PCa in Korea.Keywords
This publication has 27 references indexed in Scilit:
- Costs of Radical Prostatectomy for Prostate Cancer: A Systematic ReviewEuropean Urology, 2014
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013European Urology, 2014
- Prediction of Cancer Incidence and Mortality in Korea, 2013Cancer Research and Treatment, 2013
- Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010Cancer Research and Treatment, 2013
- Open versus robotic-assisted radical prostatectomy: which is better?Current Opinion in Urology, 2011
- Treatment costs of prostate cancer in the first year after diagnosis: a short‐term cost of illness study for France, Germany, Italy, Spain and the UKBJU International, 2009
- Retropubic, Laparoscopic, and Robot-Assisted Radical Prostatectomy: A Systematic Review and Cumulative Analysis of Comparative StudiesEuropean Urology, 2009
- Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot‐assisted techniquesBJU International, 2009
- Body-Mass Index and Mortality in Korean Men and WomenNew England Journal of Medicine, 2006
- Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancerEuropean Journal of Cardio-Thoracic Surgery, 2005